Renal Business Today

Johnson & Johnson

Anemia Study Changed Way Docs Prescribe ESAs

EXTON, Pa.—Recent clinical reports on erythropoietin-stimulating agents have changed the way nephrologists are prescribing anemia drugs, according to recent survey results from BioTrends Research ...More
April 27, 2010
Posted in News, Business, Clinical & Pharma, Practice Management
FDA to Review 3 Anemia Drugs for Safety

The U.S. Food and Drug Administration (FDA) said yesterday it would review the safety of Amgen’s Aranesp and Epogen and Johnson & Johnson’s Procrit anemia drugs after clinical trials raised "major concerns regarding the use of ESAs to increase hemoglobin concentrations" ...More
January 7, 2010
Posted in News, Business, Clinical & Pharma, Government & Regulation
Nearly Half of Dialysis Clinics Do Not Specify Hemoglobin Range

WASHINGTON—Only 56 percent of Medicare-certified dialysis clinics have anemia drug administration protocols in place that explicitly state a target hemoglobin range for patients, according to a recent government review of dialysis facilities. ...More
November 10, 2009
Posted in News, Business, Clinical & Pharma, Government & Regulation, Practice Management
Report: Product Shifts in Renal Anemia, Bone, Mineral Metabolism Markets

EXTON, Pa.—Product shifts are occurring in the renal anemia and bone and mineral metabolism markets, according to BioTrends Research Group’s most recent TreatmentTrends®: US Nephrology Report syndicated report based on online survey results of more than 200 ...More
April 28, 2009
Posted in News, Business, Clinical & Pharma, Practice Management
Va. Doctor Indicted on 45 Counts of Healthcare Fraud

VIRGINIA BEACH, Va.—Ronald Poulin, MD, a hematologist and oncologist, was indicted in federal court April 3 on charges of defrauding Medicare and Tricare, the health insurance program for military families, by more than $850,000 over the past three years, reported the ...More
April 6, 2009
Posted in News, Clinical & Pharma, Government & Regulation
FDA Releases Q&A about ESA Medication Guides

BETHESDA, Md.—FDA released answers to questions regarding the use of erythropoiesis-stimulating agents (ESAs) and their FDA-approved Medication Guides, which are now part of labeling for ESAs Aranesp®, Epogen® and Procrit®. ...More
December 9, 2008
Posted in News, Clinical & Pharma, Government & Regulation
Anemia managers placing more emphasis on IV iron

EXTON, Pa.— Anemia managers for dialysis patients are more likely to report that they are using lower average doses of erythropoiesis-stimulating agents, monitoring hemoglobins more frequently and placing more emphasis on a patient's IV iron status, according to a report ...More
September 12, 2008
Posted in News, Business, Clinical & Pharma
ESA use decreases in pre-dialysis patients, study says

EXTON, Pa.—Safety concerns regarding anemia drugs have led to a decrease in the use of erythropoiesis-stimulating agents in predialysis patients, according to a recent report. ...More
May 7, 2008
Posted in News, Business, Clinical & Pharma, Government & Regulation
Safety concerns affect anemia management

EXTON, Pa.—Approximately 80 percent of nephrologists said that safety concerns surrounding erythropoiesis-stimulating agents have affected their management of anemia, according to a new report released by BioTrends Research Group. Last year, the U.S. Food and Drug ...More
February 29, 2008
Posted in Articles, Business, Clinical & Pharma, Government & Regulation
Amgen says no to Roche’s royalty offer

ZURICH—Amgen Inc. rejected Roche’s offer to pay a licensing fee so it could launch the rival anemia drug Mircera in the United States, according to a report by Thomas Financial. ...More
February 21, 2008
Posted in News, Business, Clinical & Pharma

featured links

HOT TOPICS

Computers & Software	Consulting, Management...
Equipment & Services	Hemodialysis Supplies
Patient Services	More Options...

Johnson & Johnson

Mobile Health Snaps

Galleries

Most Popular Articles

Buyer's Guide

Resources

Free Email Updates

featured links

First Name	Last Name
E-Mail